Satellos Bioscience (MSCL.TO) will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases in Italy next month.
The biotechnology company, which is developing therapies to treat degenerative muscle diseases, said
presentations will include a poster highlighting six-month follow-up data from participants who completed the Phase 1b SAT-3247 CL-101 trial and enrolled in the current Phase 2 Trailhead trial.
SAT-3247 is an oral, small molecule drug candidate being developed as a treatment approach to regenerating skeletal muscle lost in Duchenne muscular dystrophy and other degenerative muscle diseases or injury conditions.
Price: $8.50, Change: $+0.57, Percent Change: +7.19%